Left Ventricular Non-Compaction Cardiomyopathy
Table of Contents
- Overview
- Embryology and Pathogenesis
- Genetics
- Clinical Presentation
- Diagnosis and Imaging
- Diagnostic Controversy
- Treatment
- Prognosis and Family Screening
- Research Papers
- Connections
- Featured Videos
1. Overview
Left ventricular non-compaction cardiomyopathy (LVNC) — also called non-compaction cardiomyopathy, isolated left ventricular non-compaction, or spongy myocardium — is a rare structural heart disease characterized by prominent ventricular trabeculae and deep intertrabecular recesses within the ventricular myocardium, predominantly in the left ventricle. These recesses communicate directly with the left ventricular (LV) cavity and receive blood flow from it, distinguishing LVNC from other structural abnormalities. The result is a two-layered myocardium: an outer compacted layer and an inner non-compacted, sponge-like trabeculated layer.
LVNC is classified by the American Heart Association (AHA) as a primary genetic cardiomyopathy and by the European Society of Cardiology (ESC) as an unclassified cardiomyopathy — reflecting ongoing debate about whether it represents a true distinct disease entity or a morphological trait that can accompany other cardiomyopathies. It can co-exist with hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and arrhythmogenic right ventricular cardiomyopathy (ARVC), suggesting to some investigators that prominent trabeculation is a shared morphological feature rather than an independent disease.
Clinically, LVNC presents across a wide spectrum — from asymptomatic incidental findings on echocardiography to severe heart failure, life-threatening ventricular arrhythmias, thromboembolic stroke, and sudden cardiac death. The incidence is uncertain; improved cardiac imaging with echocardiography and cardiac magnetic resonance (CMR) has dramatically increased detection rates, raising concern about over-diagnosis of the morphological finding in otherwise healthy hearts — particularly in athletes and individuals of African descent who normally have more prominent trabeculation.
Prevalence estimates range from 0.014% to 1.3% depending on population studied and diagnostic criteria applied. LVNC accounts for approximately 9% of all pediatric cardiomyopathies and is increasingly recognized in adults. The condition carries significant prognostic implications when associated with LV systolic dysfunction, arrhythmias, or genetic mutations — though the clinical significance of isolated morphological non-compaction without these features remains heavily debated.
2. Embryology and Pathogenesis
The leading hypothesis for LVNC invokes an arrest of the normal fetal myocardial compaction process. During early fetal cardiac development, the heart muscle begins as a loose meshwork of muscle fibers separated by deep recesses — a spongy, trabeculated structure that relies on intertrabecular sinusoids for oxygen and nutrient delivery before the coronary circulation is established. As the coronary arterial system matures, the myocardium undergoes progressive compaction from the epicardium inward, driven by rising intracardiac pressure and complex molecular signaling. This compaction process normally completes by approximately week 8 of gestation.
Under this model, LVNC results when the compaction process arrests prematurely, leaving persistent deep sinusoids and a hypertrabeculated inner myocardial layer. The left ventricle's apex and lateral wall — the last regions to compact — are consistently the most affected in LVNC, consistent with embryological predictions. The base of the left ventricle and the interventricular septum are relatively spared because these areas compact earliest.
However, this model has been challenged. Some investigators argue that prominent trabeculation can develop postnatally in the context of volume overload, pressure overload, or cardiomyopathic disease — not solely from fetal compaction arrest. Studies of athletes have revealed prominent trabeculation that mimics LVNC criteria on echo, and longitudinal CMR studies show that trabeculation patterns can change over time. This has fueled the view that non-compaction morphology may represent an adaptive or maladaptive response rather than a fixed developmental defect in all cases.
At the cellular level, LVNC-associated mutations disrupt sarcomere proteins, cytoskeletal elements, and mitochondrial lipid metabolism. Animal models with mutations in genes encoding sarcomere or cytoskeletal proteins develop non-compaction phenotypes, lending molecular support for the developmental arrest hypothesis while acknowledging genetic heterogeneity.
3. Genetics
LVNC demonstrates marked genetic heterogeneity. A causative mutation is identified in approximately 20–40% of cases depending on the gene panel used. Familial cases account for 18–50% of LVNC, and the inheritance pattern is most commonly autosomal dominant with variable penetrance, though X-linked and autosomal recessive forms exist.
Sarcomere gene mutations are the most common identifiable genetic cause. MYH7 (beta-myosin heavy chain) and MYBPC3 (cardiac myosin binding protein C) — the same genes most frequently mutated in hypertrophic cardiomyopathy — account for a significant proportion. This genetic overlap between LVNC and HCM is one reason some investigators argue they share pathogenic mechanisms. ACTC1 (alpha-cardiac actin), TNNT2 (cardiac troponin T), and TPM1 (tropomyosin 1) mutations have also been reported.
Cytoskeletal mutations include LDB3 (ZASP; Z-disc alternatively spliced PDZ-motif protein), which encodes a Z-disc protein important for sarcomere integrity, and DTNA (dystrobrevin alpha), a component of the dystrophin-associated protein complex. SCN5A — encoding the cardiac sodium channel Nav1.5 — links LVNC with conduction disease and arrhythmia; SCN5A loss-of-function mutations cause LVNC with prominent arrhythmic phenotype including Brugada-pattern ECG changes.
Barth syndrome is the paradigmatic X-linked form of LVNC. Caused by mutations in the TAZ gene encoding tafazzin — a mitochondrial phospholipid acyltransferase required for cardiolipin synthesis — Barth syndrome presents in males with LVNC or dilated cardiomyopathy, skeletal myopathy, growth retardation, cyclic neutropenia, and elevated urinary 3-methylglutaconic acid. Cardiolipin deficiency impairs oxidative phosphorylation and inner mitochondrial membrane integrity, explaining the multi-system phenotype.
RAS-MAPK pathway mutations (Noonan syndrome, LEOPARD syndrome) are associated with LVNC in pediatric patients, often in combination with congenital heart defects and dysmorphic features. PTPN11, RAF1, BRAF, KRAS, HRAS mutations may all produce LVNC as part of syndromic presentations.
Given the overlap with DCM and HCM gene panels, most cardiogenetics centers use comprehensive cardiomyopathy panels (50–100 genes) rather than LVNC-specific panels. A positive genetic result guides cascade family screening and may influence management decisions regarding arrhythmia risk stratification.
4. Clinical Presentation
LVNC presents across a striking clinical spectrum. A substantial minority of patients remain entirely asymptomatic — diagnosed incidentally when echocardiography is performed for unrelated reasons or during family screening after a relative is diagnosed. These patients may have normal or near-normal LV ejection fraction and may never develop complications. Whether morphological LVNC without functional impairment requires any treatment beyond surveillance is actively debated.
Heart failure is the most common symptomatic manifestation. Many patients develop a dilated cardiomyopathy phenotype — global LV dilation with reduced ejection fraction, typically 30–45%. Symptoms follow the classic HFrEF pattern: progressive exertional dyspnea, fatigue, orthopnea, and lower-extremity edema. Right heart failure can develop secondary to prolonged LV dysfunction. A subset of patients has LVNC with preserved ejection fraction (HFpEF), experiencing diastolic dysfunction and exercise intolerance with normal resting systolic function.
Ventricular arrhythmias represent the most feared complication. Non-sustained and sustained ventricular tachycardia (VT) are common — reported in up to 47% of LVNC patients in referral series. The fibrotic trabeculated myocardium provides an arrhythmogenic substrate for reentrant VT circuits. Sustained VT and ventricular fibrillation (VF) are major causes of sudden cardiac death in LVNC. Atrial fibrillation occurs in a significant proportion of patients, particularly those with LV dysfunction. Conduction disease — including bundle branch block, AV block, and accessory pathways producing Wolff-Parkinson-White-like pre-excitation — may also occur, particularly in patients with SCN5A or LDB3 mutations.
Thromboembolic events — stroke and systemic arterial embolism — are a serious and distinctive complication of LVNC. The deep intertrabecular recesses create zones of low-flow blood stasis within the trabecular network, particularly in the apical recesses of a poorly contracting ventricle. Thrombus forms within these recesses and can dislodge into the systemic circulation, causing stroke or peripheral arterial occlusion. The reported prevalence of thromboembolic events in LVNC ranges from 10–38% in older series, though contemporary anticoagulation practices may have reduced this. Young patients with stroke of undetermined etiology should prompt cardiac imaging to exclude LVNC with LV thrombus.
Pediatric LVNC often presents earlier and more severely. Neonates and infants may present with acute heart failure, hydrops fetalis, or sudden death. Syndromic LVNC (Barth syndrome, Noonan syndrome) typically presents in infancy or early childhood. The combination of LVNC with congenital heart defects — ventricular septal defect, patent ductus arteriosus, pulmonary stenosis — occurs more commonly in pediatric than adult LVNC.
5. Diagnosis and Imaging
Echocardiography is the most widely used initial imaging modality for LVNC. The Jenni criteria are the most commonly applied echocardiographic diagnostic standard:
- A two-layered myocardial structure with a non-compacted (NC) layer and a compacted (C) layer
- NC/C ratio > 2.0 measured at end-systole in the parasternal short-axis view
- Color Doppler demonstrating blood flow from the LV cavity into the deep intertrabecular recesses
- Absence of other cardiac structural abnormalities that could explain the findings
The parasternal short-axis and apical views optimally display the trabeculations. Color Doppler is essential — flow within recesses distinguishes LVNC from thrombus or other masses. The apex, lateral wall, and inferior wall are most commonly involved; the septum and basal segments are typically spared. Left ventricular function — ejection fraction, global longitudinal strain — should always be assessed alongside morphological criteria.
Cardiac magnetic resonance imaging (CMR) is considered the gold standard for LVNC diagnosis. CMR provides superior endocardial border definition compared to echocardiography and allows accurate measurement of the trabeculated and compacted layers throughout the cardiac cycle. Two major CMR-based criteria are used:
- Petersen criteria: NC/C ratio > 2.3 measured in diastole
- Jacquier criteria: trabeculated LV mass > 20% of total LV mass
CMR also provides tissue characterization through late gadolinium enhancement (LGE) — focal areas of gadolinium retention in the myocardium indicate fibrosis and are associated with worse prognosis, higher arrhythmia risk, and worse systolic function. LGE-positive LVNC patients have higher rates of VT, hospitalization for heart failure, and adverse events compared to LGE-negative patients. Additionally, CMR can identify right ventricular involvement and quantify RV function — relevant because RV non-compaction can occur concomitantly in a minority of patients.
Genetic testing with a comprehensive cardiomyopathy gene panel (MYH7, MYBPC3, TAZ, LDB3, SCN5A, ACTC1, TNNT2, LMNA, and others) is recommended in all patients with confirmed LVNC. A positive result identifies at-risk family members for cascade screening and may influence arrhythmia risk stratification — particularly for mutations in LMNA and SCN5A, which carry higher arrhythmia risk independent of EF.
Electrocardiography often shows nonspecific abnormalities: LV hypertrophy pattern, left bundle branch block, ST-T changes, or Q waves. WPW-like delta waves occur in a subset, particularly with SCN5A mutations. Ambulatory monitoring (Holter) is essential to detect non-sustained VT, which influences ICD decision-making.
6. Diagnostic Controversy and the Over-Diagnosis Problem
A vigorous debate surrounds whether LVNC is a distinct disease entity or an overdiagnosed morphological variant. Several lines of evidence fuel this controversy:
Normal hearts with trabeculation: Population-based CMR studies reveal that prominent trabeculation meeting standard LVNC criteria is present in 15–25% of otherwise healthy adults — far exceeding the expected disease prevalence. Athletes, particularly endurance athletes, show increased trabeculation that may meet diagnostic thresholds for LVNC yet carries no adverse prognosis. Individuals of African descent have systematically higher trabeculation indices than Europeans in population studies, meaning race-specific normal reference ranges may be necessary to avoid diagnostic disparities.
No consistent phenotype: Patients who meet morphological LVNC criteria span an enormous clinical range — from athletes with structurally normal hearts to patients with severe DCM and life-threatening arrhythmias. If morphological criteria alone cannot predict clinical phenotype or outcomes, the criteria may be identifying a heterogeneous group rather than a coherent disease.
Genetic non-specificity: LVNC-associated mutations overlap substantially with HCM and DCM mutations. A patient with an MYH7 mutation might be classified as HCM, DCM, or LVNC depending on which phenotypic feature is dominant. Some investigators argue that LVNC morphology is simply a secondary feature that can accompany various cardiomyopathies rather than defining a separate entity.
Current consensus suggests that the diagnosis of clinically significant LVNC requires both morphological criteria AND clinical context: LV dysfunction, symptoms, arrhythmias, family history, or pathogenic genetic mutations. Isolated morphological non-compaction in an otherwise healthy person — particularly an athlete — should be interpreted with caution and may represent a normal variant. The 2023 ESC Cardiomyopathy Guidelines acknowledge this uncertainty and emphasize phenotypic and genetic evaluation alongside morphological imaging.
7. Treatment
There is no specific pharmacological therapy targeting the non-compaction defect itself. Treatment is directed at the complications of LVNC: heart failure, arrhythmias, thromboembolism, and sudden cardiac death.
Heart failure management follows the same evidence-based framework as other forms of heart failure with reduced ejection fraction (HFrEF). The four pillars of guideline-directed medical therapy (GDMT) apply equally to LVNC-associated DCM phenotype:
- ACE inhibitors or ARBs / ARNI (sacubitril-valsartan, preferred over ACEi in symptomatic HFrEF per PARADIGM-HF): reduce afterload, attenuate neurohormonal activation, promote reverse remodeling
- Beta-blockers (carvedilol, metoprolol succinate, bisoprolol): reduce sympathetic tone, lower heart rate, improve LV function over time
- Mineralocorticoid receptor antagonists (spironolactone, eplerenone): reduce fluid retention and fibrosis
- SGLT2 inhibitors (dapagliflozin, empagliflozin): reduce hospitalization and cardiovascular death in HFrEF independent of diabetes status
Device therapy follows standard HFrEF criteria. Implantable cardioverter-defibrillator (ICD) implantation is indicated when LVEF remains below 35% despite at least 3 months of optimal GDMT, or for secondary prevention after documented sustained VT or VF regardless of EF. Certain genetic mutations — particularly LMNA and SCN5A — carry sufficient arrhythmia risk that ICD implantation may be considered at higher EF thresholds. Cardiac resynchronization therapy (CRT) is indicated when LVEF <35%, left bundle branch block (LBBB), and QRS duration >150 ms are present — the same criteria as other HFrEF etiologies.
Anticoagulation for thromboembolic prevention is one of the most debated management decisions in LVNC. Established indications include atrial fibrillation and prior thromboembolic event. The appropriate threshold for anticoagulating patients in sinus rhythm with reduced EF but no prior event is unclear. Many centers anticoagulate patients with LVEF <35–40% empirically given the risk of thrombus formation within intertrabecular recesses, using warfarin or direct oral anticoagulants (DOACs). Regular echocardiographic assessment for LV thrombus guides ongoing anticoagulation decisions.
Antiarrhythmic therapy: Atrial fibrillation is managed with standard rate or rhythm control strategies plus anticoagulation. For ventricular arrhythmias — VT storm or recurrent ICD shocks — amiodarone or catheter ablation targeting the arrhythmic circuits within the trabeculated myocardium can reduce burden. Catheter ablation in LVNC is technically challenging given the complex trabecular anatomy.
Heart transplantation is the definitive treatment for refractory advanced heart failure refractory to GDMT and device therapy. LVNC patients tolerate transplantation well, with post-transplant outcomes comparable to other cardiomyopathy etiologies. Left ventricular assist device (LVAD) implantation serves as a bridge to transplantation or as destination therapy for patients ineligible for transplant.
Exercise restriction is individualized. Competitive sports are generally restricted for patients with significant LV dysfunction, sustained ventricular arrhythmias, or ICD in place. Patients with isolated morphological LVNC and normal LV function may participate in recreational physical activity with periodic monitoring.
8. Prognosis and Family Screening
Prognosis in LVNC is highly variable and strongly tied to LV systolic function. Patients with preserved ejection fraction and no significant arrhythmias may have an essentially normal life expectancy if carefully monitored. In contrast, patients presenting with severe LV dysfunction (LVEF <30%), sustained VT, or prior cardiac arrest carry a substantially elevated risk of death, transplantation, or major adverse cardiac events.
Long-term outcomes from referral cohorts — which are biased toward more severely affected patients — have reported 5-year event-free survival (death, transplantation, major thromboembolic event) of 50–60%. However, registry data from broader population-based screening suggest that many patients with LVNC detected incidentally or with preserved function have a far more benign course. The presence of LGE on CMR, reduced LV global longitudinal strain, and causative genetic mutations (particularly LMNA) identifies a higher-risk subgroup.
Family screening is a critical management component. LVNC is familial in 18–50% of cases, with autosomal dominant transmission in most. Current guidelines recommend echocardiographic screening of all first-degree relatives (parents, siblings, children) of a confirmed LVNC patient. CMR is preferred in equivocal cases. Relatives found to have morphological non-compaction alone — without symptoms or dysfunction — require periodic monitoring every 3–5 years given age-dependent penetrance. When a pathogenic mutation is identified in the proband, genetic cascade testing allows relatives to be risk-stratified before cardiac abnormalities develop.
Children of LVNC patients should be screened beginning in infancy or early childhood given the occurrence of pediatric-onset disease. Barth syndrome — X-linked TAZ mutations — has a high mortality in infancy without aggressive management, and neonatal screening programs are being developed for at-risk families.
9. Research Papers
- Jenni R, et al. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. Heart. 2001;86(6):666–671. PMID: 11711464. DOI: 10.1136/heart.86.6.666
- Petersen SE, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005;46(1):101–105. PMID: 15992642. DOI: 10.1016/j.jacc.2005.03.045
- Arbustini E, et al. Left ventricular noncompaction: a distinct genetic cardiomyopathy? J Am Coll Cardiol. 2016;68(9):949–966. PMID: 27561765. DOI: 10.1016/j.jacc.2016.05.089
- Ichida F, et al. Clinical features of isolated noncompaction of the ventricular myocardium: long-term clinical course, hemodynamic properties, and genetic background. J Am Coll Cardiol. 1999;34(1):233–240. PMID: 10400016. DOI: 10.1016/s0735-1097(99)00170-9
- Towbin JA, et al. Left ventricular non-compaction cardiomyopathy. Lancet. 2015;386(9995):813–825. PMID: 26164915. DOI: 10.1016/S0140-6736(14)61282-4
- Jacquier A, et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J. 2010;31(9):1098–1104. PMID: 20173210. DOI: 10.1093/eurheartj/ehp595
- Captur G, et al. Left ventricular non-compaction: Genetic basis, clinical manifestation and management. Heart. 2015;101(17):1365–1372. PMID: 26036770. DOI: 10.1136/heartjnl-2014-307055
- Bhatia NL, et al. Isolated noncompaction of the left ventricular myocardium in adults: a systematic overview. J Card Fail. 2008;14(2):149–153. PMID: 18325462. DOI: 10.1016/j.cardfail.2007.10.023
- Muser D, et al. Long-term outcome after catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy. Circ Arrhythm Electrophysiol. 2016;9(10):e004337. PMID: 27729346. DOI: 10.1161/CIRCEP.116.004337
- Fazio G, et al. Left ventricular non compaction with arrhythmias: A paediatric disease, an adult disease or both? Cardiology. 2012;121(4):212–216. PMID: 22572601. DOI: 10.1159/000336843
- Aung N, et al. Genome-wide analysis of left ventricular trabeculation identifies novel genetic loci and provides insights into the genetic architecture. Nat Genet. 2022;54(7):1032–1042. PMID: 35726092. DOI: 10.1038/s41588-022-01124-8
- Oechslin E, Jenni R. Left ventricular non-compaction revisited: a distinct phenotype with genetic heterogeneity? Eur Heart J. 2011;32(12):1446–1456. PMID: 21406440. DOI: 10.1093/eurheartj/ehq508
10. Connections
- Cardiomyopathy Overview
- Hypertrophic Cardiomyopathy (HCM)
- Dilated Cardiomyopathy (DCM)
- Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
- Heart Failure
- Arrhythmia
- Ventricular Tachycardia
- Ventricular Fibrillation
- Sudden Cardiac Death
- Long QT Syndrome
- Atrial Fibrillation
- Stroke
11. Featured Videos
